Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Non-Current Liabilities (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 12 years of Other Non-Current Liabilities data on record, last reported at $29.3 million in Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities rose 8.26% year-over-year to $29.3 million; the TTM value through Sep 2025 reached $29.3 million, up 8.26%, while the annual FY2024 figure was $20.9 million, 7.8% down from the prior year.
  • Other Non-Current Liabilities reached $29.3 million in Q3 2025 per AMPH's latest filing, up from $27.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $29.3 million in Q3 2025 and bottomed at $4.7 million in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $15.6 million, with a median of $15.2 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 65.6% in 2024, then surged 358.23% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $15.7 million in 2021, then fell by 6.95% to $14.6 million in 2022, then surged by 55.98% to $22.7 million in 2023, then dropped by 7.8% to $20.9 million in 2024, then soared by 39.74% to $29.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $29.3 million in Q3 2025, $27.8 million in Q2 2025, and $24.4 million in Q1 2025.